iRhythm Technologies (NASDAQ:IRTC) Shares Down 6.5% Following Analyst Downgrade

Key Points

• Shares fell 6.5% after Wells Fargo cut its price target from $200 to $180 (retaining an overweight rating); IRTC traded as low as $120.06 and last at $120.78 on below‑average volume (~209,752 shares, down 66% vs. the average).
• Q1 beat expectations: iRhythm reported EPS of ($0.35) vs. ($0.66) est. and revenue of $199.4M vs. $194.1M est. (revenue +25.6% YoY), but the company remains unprofitable with negative net margin and ROE.
• Analyst views are mixed—consensus is a “Moderate Buy” with an average price target of $202.23 while some firms cut targets and others raised them—and insiders sold about 94,509 shares (~$12.7M) over the last three months.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report)'s stock price fell 6.5% on Friday after Wells Fargo & Company lowered their price target on the stock from $200.00 to $180.00. Wells Fargo & Company currently has an overweight rating on the stock. iRhythm Technologies traded as low as $120.06 and last traded at $120.7760. 209,752 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 619,346 shares. The stock had previously closed at $129.16.

Several other brokerages also recently weighed in on IRTC. Truist Financial cut their price objective on shares of iRhythm Technologies from $200.00 to $170.00 and set a "buy" rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen downgraded shares of iRhythm Technologies from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Robert W. Baird dropped their target price on shares of iRhythm Technologies from $220.00 to $200.00 and set an "outperform" rating on the stock in a report on Friday, February 20th. Evercore raised shares of iRhythm Technologies from an "in-line" rating to an "outperform" rating and lifted their target price for the stock from $194.00 to $210.00 in a research report on Monday, January 5th. Finally, Freedom Capital raised shares of iRhythm Technologies to a "strong-buy" rating in a research report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $202.23.

Insider Buying and Selling at iRhythm Technologies

In other news, EVP Minang Turakhia sold 4,027 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $128.45, for a total transaction of $517,268.15. Following the completion of the sale, the executive vice president owned 54,906 shares in the company, valued at $7,052,675.70. The trade was a 6.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Patrick Michael Murphy sold 4,357 shares of iRhythm Technologies stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total transaction of $559,613.08. Following the sale, the insider owned 63,203 shares of the company's stock, valued at approximately $8,117,793.32. This represents a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 94,509 shares of company stock valued at $12,734,195 over the last three months. Insiders own 1.10% of the company's stock.

iRhythm Technologies News Roundup

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat expectations: iRhythm reported EPS of ($0.35) vs. consensus ($0.66) and revenue of $199.4M (vs. $194.1M est.), with revenue up ~25.6% YoY — this shows improving top-line momentum and narrower losses. MarketBeat Q1 results
• Positive Sentiment: Analyst bullishness: Needham raised its price target to $255 and kept a Buy rating, signaling strong upside expectations from some sell‑side analysts. Benzinga note on Needham
• Positive Sentiment: Market expansion, margin gains and AI/regulatory tailwinds highlighted in recent coverage — these catalysts could support longer‑term revenue and margin improvement if execution continues. MSN deep dive
• Neutral Sentiment: FY‑2026 revenue guidance was provided (~$875–$885M), which is essentially in line with consensus (~$876M); EPS guidance was unclear in the release — mixed signal that tempers the beat. Company press release / slide deck
• Neutral Sentiment: Full Q1 materials and the earnings call transcript are available for deeper due diligence (useful for evaluating management commentary on margins, utilization and reimbursement). Seeking Alpha transcript
• Negative Sentiment: Not all analysts are upbeat — Truist cut its price target in a healthcare sector preview, reflecting more cautious sentiment that could weigh on near‑term shares. Yahoo/Truist note
• Negative Sentiment: Company remains unprofitable with negative net margin and ROE; investors sensitive to profitability timelines may sell into the beat, keeping pressure on the stock. Zacks coverage

Institutional Investors Weigh In On iRhythm Technologies

Several institutional investors have recently modified their holdings of the business. Tudor Investment Corp ET AL acquired a new stake in shares of iRhythm Technologies during the 3rd quarter worth approximately $3,439,800,000. Vanguard Group Inc. grew its position in shares of iRhythm Technologies by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 3,310,519 shares of the company's stock worth $587,418,000 after buying an additional 70,420 shares during the period. RTW Investments LP acquired a new stake in shares of iRhythm Technologies during the 4th quarter worth approximately $209,732,000. Geode Capital Management LLC grew its position in shares of iRhythm Technologies by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 858,405 shares of the company's stock worth $152,337,000 after buying an additional 68,301 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of iRhythm Technologies by 45.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 829,862 shares of the company's stock worth $147,251,000 after buying an additional 259,800 shares during the period.

iRhythm Technologies Stock Performance

The firm's 50-day moving average price is $122.93 and its 200 day moving average price is $154.60. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63. The company has a market cap of $4.00 billion, a price-to-earnings ratio of -84.56 and a beta of 1.18.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.31. The firm had revenue of $199.39 million during the quarter, compared to the consensus estimate of $194.11 million. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The business's quarterly revenue was up 25.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.97) earnings per share. On average, sell-side analysts anticipate that iRhythm Technologies will post -0.16 EPS for the current year.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.